HC Wainwright Issues Pessimistic Estimate for MIRM Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Analysts at HC Wainwright reduced their Q3 2026 EPS estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Monday, May 4th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.25) for the quarter, down from their prior forecast of ($0.18). HC Wainwright has a “Buy” rating and a $175.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.80) EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The business had revenue of $148.93 million for the quarter, compared to the consensus estimate of $141.78 million. During the same quarter in the previous year, the business earned $1.00 earnings per share. The firm’s revenue was up 49.8% on a year-over-year basis.

A number of other research firms have also weighed in on MIRM. Citizens Jmp reissued a “market outperform” rating and set a $132.00 price objective on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 21st. Stifel Nicolaus increased their price objective on Mirum Pharmaceuticals from $125.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Morgan Stanley increased their price objective on Mirum Pharmaceuticals from $130.00 to $140.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Evercore set a $126.00 price objective on Mirum Pharmaceuticals in a research note on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $125.25.

Mirum Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ MIRM opened at $105.81 on Wednesday. The stock has a market capitalization of $6.45 billion, a P/E ratio of -220.43 and a beta of 0.52. Mirum Pharmaceuticals has a one year low of $40.00 and a one year high of $110.49. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. The firm’s 50 day simple moving average is $93.79 and its two-hundred day simple moving average is $85.61.

Insiders Place Their Bets

In related news, CEO Christopher Peetz sold 40,985 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $3,769,800.30. Following the sale, the chief executive officer owned 194,309 shares in the company, valued at $17,872,541.82. The trade was a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Peter Radovich sold 16,515 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $1,519,049.70. Following the completion of the sale, the chief operating officer owned 40,272 shares in the company, valued at approximately $3,704,218.56. This trade represents a 29.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 76,806 shares of company stock valued at $7,064,616 over the last quarter. 22.87% of the stock is owned by company insiders.

Institutional Trading of Mirum Pharmaceuticals

Several large investors have recently added to or reduced their stakes in MIRM. Allspring Global Investments Holdings LLC purchased a new stake in Mirum Pharmaceuticals in the first quarter worth $232,000. Bank of New York Mellon Corp boosted its holdings in shares of Mirum Pharmaceuticals by 3.3% during the 1st quarter. Bank of New York Mellon Corp now owns 584,523 shares of the company’s stock valued at $53,998,000 after buying an additional 18,944 shares in the last quarter. Hillsdale Investment Management Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 25.4% during the 1st quarter. Hillsdale Investment Management Inc. now owns 59,730 shares of the company’s stock valued at $5,518,000 after buying an additional 12,100 shares in the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in shares of Mirum Pharmaceuticals by 3.3% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 250,399 shares of the company’s stock valued at $23,132,000 after buying an additional 8,079 shares in the last quarter. Finally, Emerald Advisers LLC boosted its holdings in shares of Mirum Pharmaceuticals by 8.2% during the 1st quarter. Emerald Advisers LLC now owns 397,263 shares of the company’s stock valued at $36,699,000 after buying an additional 30,129 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.